Form 4: BiomX Inc. CEO Jonathan Solomon Acquires 3,805,000 Stock Options

BiomX Inc. CEO Jonathan Eitan Solomon reports the acquisition of 3,805,000 stock options with a vesting schedule over four years.

Summary

• On July 11, 2024, Jonathan Eitan Solomon, CEO of BiomX Inc., acquired 3,805,000 options to purchase common stock.
• The exercise price of these options is $0.363.
• The options vest over four years, with 25% vesting on July 11, 2025, and the remaining 75% vesting in 12 equal quarterly installments over the subsequent three years.
• The expiration date for these options is July 11, 2034.
• The reporting person directly owns the options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The acquisition of options by the CEO can be seen as a positive signal, but it's not overwhelmingly so.

Positives

• The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The vesting schedule means the CEO's benefit from these options is tied to continued service and potentially the company's performance over the next four years.

Industry Context

This is a standard practice for incentivizing and retaining key executives in publicly traded companies, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Granting stock options to CEOs is a common practice across the biotechnology industry.
• The vesting schedule and exercise price would need to be compared to similar grants at peer companies to determine if they are in line with industry standards.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view this as a positive incentive for the CEO to increase company value.
• Employees may see this as a sign of stability and commitment from the leadership.

Key Dates